Issued: Monday 2 February 2009, London UK - LSE Announcement
GlaxoSmithKline plc, announces board changes
GlaxoSmithKline plc (GSK) announces that Mr. James Murdoch has been appointed a Non-Executive Director and will join the Board of the Company with effect from 20th May 2009. On appointment, James will also become a member of GSK's Corporate Responsibility Committee. James is Chairman and Chief Executive of News Corporation Europe and Asia.
It is also announced that Sir Ian Prosser and Dr Ronaldo Schmitz will retire from the Board at the conclusion of the Annual General Meeting on 20th May 2009.
Commenting on the changes, Sir Christopher Gent, Chairman of GSK, said:
"I am delighted to welcome James to the Board of GSK. His experience of global business, marketing and communications will bring a unique and alternative perspective to the Board. He will also be an excellent addition to the Board's Corporate Responsibility Committee, an area where he has shown particular leadership at BSkyB and News Corporation.
"I would like to thank both Sir Ian and Ronaldo for their dedicated service to the Boards of GSK and the heritage companies. I have always valued their support and wish them well for the future."
Sir Robert Wilson will succeed Sir Ian as GSK's Senior Independent Non-Executive Director. Sir Robert will step down as Chairman of the Remuneration Committee and will be succeeded by Sir Crispin Davis. Professor Sir Roy Anderson will also join the Audit Committee with effect from 20th May 2009.
Biographical details of James Murdoch are given below.
S M Bicknell
Company Secretary
02 February 2009 Biographical details
James Murdoch was appointed Chairman and Chief Executive, News Corp, Europe and Asia, in 2007. In this role, he has direct responsibility for the strategic and operational development of News Corporation's television, newspaper and related digital assets in Europe, Asia and the Middle East. At the same time, James was appointed Non-Executive Chairman of BSkyB and re-joined the Board of News Corporation. James served as Chief Executive Officer of BSkyB from 2003 to 2007 and was previously Chairman and CEO of Star TV.
James serves on the Board of Yankee Global Enterprises, the Board of Trustees of the Harvard Lampoon and the Leadership Council of The Climate Group.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
Enquiries: |
|
|
UK Media enquiries: |
Philip Thomson |
(020) 8047 5502 |
|
Alice Hunt |
(020) 8047 5502 |
|
David Outhwaite |
(020) 8047 5502 |
|
Stephen Rea |
(020) 8047 5502 |
|
|
|
US Media enquiries: |
Nancy Pekarek |
(919) 483 2839 |
|
Mary Anne Rhyne |
(919) 483 2839 |
|
Kevin Colgan |
(919) 483 2839 |
|
Sarah Alspach |
(215) 751 7709 |
|
|
|
European Analyst/Investor enquiries: |
David Mawdsley |
(020) 8047 5564 |
|
Sally Ferguson |
(020) 8047 5543 |
|
Gary Davies |
(020) 8047 5503 |
|
|
|
US Analyst/ Investor enquiries: |
Tom Curry |
(215) 751 5419 |
|
Jen Hill |
(215) 751 7002 |
Cautionary statement regarding forward-looking statements |
Registered in England & Wales: No. 3888792 |
|
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS |